| 摘要 |
A ziprasidone besylate of crystalline is provided to ensure excellent stability, solubility, non-hydroscopicity and higher elution rate than ziprasidone hydrochloride. A method for manufacturing a ziprasidone besylate of crystalline comprises: a step of reacting ziprasidone and benzenesulfonic acid in inert solvent; and a cooling the mixture to -10~10°C. The inert solvent is acetone, ethyl acetate, methanol, ethanol, isopropanol, acetonitrile, isopropyl ether, methyl ethyl ketone, dichloromethane, tetrahydrofuran or their mixture. A composition for treating schizophrenia or bipolar disorder-related mania comprises ziprasidone besylate and pharmaceutically allowable carrier.
|
